
China Biological COVID-19 inactivated vaccine was held in Beijing, Wuhan and Abu Dhabi of UAE in the form of video conference. The health minister of UAE issued the clinical trial approval document to Sinopharm China biology. China and Abu Dhabi signed relevant clinical cooperation agreements on the spot, which also marks the official launch of the world's first international clinical trial (phase III) of inactivated COVID-19 vaccine.
PROCESS:
(1) The Ministry of Health or CDC of the third country shall issue a valid document according to the format given by our company.
(2) Valid Proof of Funds.
(3) The purchasing country should submit the list of participants and their positions as soon as possible, and come to China to negotiate the cooperation details with our company.
(4) Formal signing. The contract signing process will be led by our company, and the two parties coordinated to arrange the cooperation and achievement.
(5) After signing the contract, different quantities of clinical trial vaccines will be supplied. (The exact quantity is determined according to the purchaser’s requirement).
(6) The subject product of the procurement contract is the finished vaccine, which is expected to begin to launched to the market between mid-October and the end of October. The procurement contract must be signed 20 to 25 days in advance.
(7) Payment method: Full payment with TT.